Budicort Turbuhaler

/ Astra Zeneca

The dosage of Budicort Turbuhaler is individual.
Budicort Turbuhaler is for oral inhalation.
When transferring patients to Turbuhaler from other devices, treatment should be individualised, The drug and method of delivery should be considered.
The dosage should be individualised.
The dose should always be reduced to the minimum needed to maintain good asthma control.
Adults (including elderly) and children over 12 years of age: When starting treatment, during periods of severe asthma and while reducing or discontinuing oral glucocorticosteroids, the dosage in adults should be 200 – 1600 micrograms daily, divided into 2-4 administrations.
In less severe cases and children over 12 years of age, 200 – 800 micrograms daily, in divided doses, may be used. During periods of severe asthma, the daily dosage can be increased to up to 1600 micrograms, in 2-4 divided doses.
Children 6 years-12 years of age: 200 – 800 micrograms daily, in divided doses. During periods of severe asthma, the daily dose can be increased up to 800 micrograms.
The maintenance dose should be the lowest possible.
It is possible that the patient will not taste or perceive any medicine when Budicort Turbuhaler is used; this is because such a small amount of substance is dispensed.
In patients where an increased therapeutic effect is desired, an increased dose of Budicort is recommended because of the lower risk of systemic effects as compared with a combined treatment with oral glucocorticosteroids.
See prescribing information for full details.

Budicort is recommended in patients with bronchial asthma.

Hypersensitivity to budesonide.

Pregnancy and lactation. Patients with lung tuberculosis and fungal and viral infections in the airways.
See prescribing information for full details.

Common (>1/100): Airways: Candida infections in the oral cavity and throat, mild throat irritation, cough, hoarseness.
See prescribing information for full details.

Budesonide has not been observed to interact with any drug used for the treatment of asthma or COPD.
At recommended doses, cimetidine has slight but clinically insignificant effect on the pharmacokinetics of oral budesonide.
No clinically relevant interactions with other agents for asthma are known.
See prescribing information for full details.

Pregnancy: Data on approximately 2000 exposed pregnancies indicate no increased teratogenic risk associated with the use of inhaled budesonide. Animal studies have shown that, glucocorticosteroids can induce malformations, but with the recommended dosage this is judged not to be relevant for humans.
Lactation: Budesonide is excreted in breast milk. However, at therapeutic doses of Budicort Turbuhaler no effects on the suckling child are anticipated. Budicort
Turbuhaler can be used during breast-feeding.

Acute overdose with Budicort Turbuhaler, even in high doses, is not expected to cause any clinical problems. If used chronically in high doses, systemic effects of glucocorticosteroids such as hypercortisolism and adrenal suppression can occur.